# A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma

> **NCT02794519** · PHASE2 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Sirukumab
- **DRUG:** Placebo
- **DRUG:** Rescue medication

## Key facts

- **NCT ID:** NCT02794519
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-09-23
- **Primary completion:** 2016-10-04
- **Final completion:** 2016-10-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study has suspended participant recruitment.
- **Last updated:** 2018-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02794519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02794519, "A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT02794519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*